The fuel gauge showed just a tiny amount of hydrogen in the vehicle’s tank, and someone on the sales staff at Roseville ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free for over 18 years thanks to CAR T-cell therapy ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...